Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...

The Biden administration’s selection of 15 new drugs for price negotiations is reigniting the call from opponents to amend how drugs can be selected for the Medicare program.

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Industry group PhRMA slams Medicare's Inflation Reduction Act, alleging failure to regulate PBMs and insurers as Medicare ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

Novo NOrdisk (NVO) stock drops as Medicare selects 15 additional Part D drugs including its weight loss drug Wegovy for ...